Payment overview · 2025
General Payments
$4,428.29
70 reported records · 23 companies
Healthcare provider profile · identity verified
Matthew Samra, D.O
Allopathic & Osteopathic Physicians|Surgery|Vascular Surgery · NEPTUNE CITY, NJ · NPI 1225171382
Verified facts
What the public records show
CMS Open Payments records show Matthew Samra, D.O received $4,428.29 in general payments during 2025 across 70 reported records.
Boston Scientific Corporation accounted for 38.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $1,683.03 | 38.0% | 14 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $344.10 | 7.8% | 7 | 2025 |
| LeMaitre Vascular, Inc. | Unresolved — no canonical attribution shown | $286.85 | 6.5% | 3 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $263.25 | 5.9% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $254.64 | 5.8% | 4 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $225.31 | 5.1% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $215.59 | 4.9% | 4 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $210.12 | 4.7% | 2 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $206.55 | 4.7% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$169.64 | 3.8% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $90.40 | 2.0% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $84.52 | 1.9% | 3 | 2025 |
| BIOTRONIK INC. | Unresolved — no canonical attribution shown | $76.24 | 1.7% | 3 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $59.37 | 1.3% | 3 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $56.20 | 1.3% | 3 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $52.45 | 1.2% | 3 | 2025 |
| Acera Surgical, Inc. | Unresolved — no canonical attribution shown | $34.38 | 0.8% | 2 | 2025 |
| Musculoskeletal Transplant Foundation Inc. | Unresolved — no canonical attribution shown | $27.98 | 0.6% | 2 | 2025 |
| Humacyte Global, Inc. | Unresolved — no canonical attribution shown | $19.59 | 0.4% | 1 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $19.43 | 0.4% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $17.72 | 0.4% | 1 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $15.72 | 0.3% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $15.21 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,254.40 | 64 |
| Travel and Lodging | $1,173.89 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| General - Therapies Normalized: general therapies |
Device | Boston Scientific Corporation | $1,243.19 | 7 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $328.85 | 2 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $263.25 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $263.25 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $254.64 | 4 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $254.64 | 4 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $254.64 | 4 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $210.12 | 2 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $209.97 | 6 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $206.55 | 1 | 2025 |
Source payment records
|
|||||
| RESTOREFLOW Normalized: restoreflow |
Device | LeMaitre Vascular, Inc. | $170.05 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $169.64 | 2 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis Normalized: gore excluder thoracoabdominal branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $167.27 | 2 | 2025 |
Source payment records
|
|||||
| XIENCE SKYPOINT Normalized: xience skypoint |
Device | Abbott Laboratories | $143.94 | 1 | 2025 |
Source payment records
|
|||||
| GORE TAG Conformable Thoracic Endoprosthesis Normalized: gore tag conformable thoracic endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $125.87 | 1 | 2025 |
Source payment records
|
|||||
| Zenition 90 Normalized: zenition 90 |
Device | Philips North America LLC | $90.40 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $84.52 | 3 | 2025 |
Source payment records
|
|||||
| SYNTEL EMBOLECTOMY CATHETER (SPRING TIP) Normalized: syntel embolectomy catheter spring tip |
Device | LeMaitre Vascular, Inc. | $75.93 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $59.37 | 3 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $59.37 | 3 | 2025 |
Source payment records
|
|||||
| INNOVAMATRIX AC Normalized: innovamatrix ac |
Device | ConvaTec Inc. | $56.20 | 3 | 2025 |
Source payment records
|
|||||
| Pulsar-18 T3 Normalized: pulsar 18 t3 |
Device | BIOTRONIK INC. | $45.05 | 2 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $40.99 | 2 | 2025 |
Source payment records
|
|||||
| ARTEGRAFT VASCULAR GRAFT Normalized: artegraft vascular graft |
Device | LeMaitre Vascular, Inc. | $40.87 | 1 | 2025 |
Source payment records
|
|||||
| Restrata Wound Matrix Normalized: restrata wound matrix |
Device | Acera Surgical, Inc. | $34.38 | 2 | 2025 |
Source payment records
|
|||||
| ARROW Normalized: arrow |
Device | Teleflex LLC | $33.97 | 2 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $31.28 | 1 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $30.66 | 1 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $29.32 | 1 | 2025 |
Source payment records
|
|||||
| GORE EXCLUDER Iliac Branch Endoprosthesis Normalized: gore excluder iliac branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $26.79 | 2 | 2025 |
Source payment records
|
|||||
| GORE TAG Thoracic Branch Endoprosthesis Normalized: gore tag thoracic branch endoprosthesis |
Device | W. L. Gore & Associates, Inc. | $24.17 | 2 | 2025 |
Source payment records
|
|||||
| ENROUTE Transcarotid Neuroprotection System Normalized: enroute transcarotid neuroprotection system |
Device | Boston Scientific Corporation | $22.52 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $21.69 | 1 | 2025 |
Source payment records
|
|||||
| Symvess Normalized: symvess |
Biological | Humacyte Global, Inc. | $19.59 | 1 | 2025 |
Source payment records
|
|||||
| RENASYS TOUCH Normalized: renasys touch |
Device | Smith+Nephew, Inc. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $15.72 | 1 | 2025 |
Source payment records
|
|||||
| LifeStream Normalized: lifestream |
Device | Bard Peripheral Vascular, Inc. | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $15.21 | 1 | 2025 |
Source payment records
|
|||||
| General - Atherectomy Normalized: general atherectomy |
Device | Boston Scientific Corporation | $6.18 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 58 | 36 |
| Oxycodone Hcl | Oxycodone Hcl | 47 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 28 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 21 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Tramadol Hcl | Tramadol Hcl | 14 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,428.29 · 70 records | Boston Scientific Corporation | ARROW, ARTEGRAFT VASCULAR GRAFT, AURYON LASER SYSTEM 100-120 VAC, Barostim Neo System, ELUVIA, ENDOCROSS Device, ENDURANT IIS, ENROUTE Transcarotid Neuroprotection System, ESPRIT, Flexitouch Plus, GORE EXCLUDER Iliac Branch Endoprosthesis, GORE EXCLUDER Thoracoabdominal Branch Endoprosthesis, GORE TAG Conformable Thoracic Endoprosthesis, GORE TAG Thoracic Branch Endoprosthesis, General - Atherectomy, General - Therapies, General - Vascular Intervention, INNOVAMATRIX AC, Indigo System, Integra, Integra Dermal Regeneration Template, LifeStream, Nimbl, PRIMATRIX, Pulsar-18 T3, RENASYS TOUCH, RESTOREFLOW, Ranger, Restrata Wound Matrix, RotarexS 6 F x 135 cm, SUPERA, SYNTEL EMBOLECTOMY CATHETER (SPRING TIP), Senza, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, Symvess, Topical Oxygen Chamber for extremities, Torus Stent Graft System, Varithena Administration Pack, XIENCE SKYPOINT, Zenition 90 | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error